Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. While current state-of-the-art antibody discovery and optimization techniques may take months of laborious laboratory procedures executed by highly-skilled practitioners, Protillion's high throughput instrumentation can characterize the binding affinity on the order of 1 million antibody variants in a 2-day automated run. Our unique approach enables the identification of better antibody candidates on an exponentially faster timeline.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/19/22 | $18,000,000 | Series A |
ARCH Venture Partners Illumina Ventures | undisclosed |
